Novo Nordisk: FDA approves new indication for Victoza.
(CercleFinance.com) - Denmark's Novo Nordisk won US approval on Friday for its type-2 diabetes treatment Victoza to reduce the risk of major adverse cardiovascular events.
More specifically, the Food and Drug Administration (FDA) approved a new indication for Victoza to reduce the risk of major adverse cardiovascular (CV) events in adults with type-2 diabetes and established CV disease.
The drug is now the only type-2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events.
The FDA's decision is based on the results from a clinical trial which demonstrated that Victoza statistically significantly reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 13% versus placebo.
Novo Nordisk shares are currently up 0.6% in early morning trading after these results.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
More specifically, the Food and Drug Administration (FDA) approved a new indication for Victoza to reduce the risk of major adverse cardiovascular (CV) events in adults with type-2 diabetes and established CV disease.
The drug is now the only type-2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events.
The FDA's decision is based on the results from a clinical trial which demonstrated that Victoza statistically significantly reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 13% versus placebo.
Novo Nordisk shares are currently up 0.6% in early morning trading after these results.
Copyright (c) 2017 CercleFinance.com. All rights reserved.